SeattleGenetics®

Fact Sheet

NOVEMBER 2017

Empowered

THERAPIES • ANTIBODIES • SCIENCE

ADCETRIS®
brentuximab vedotin | for injection

Quick Facts

- Approved in the U.S. for four indications for treatment of adult patients:
  - Relapsed classical Hodgkin lymphoma
  - Relapsed systemic anaplastic large cell lymphoma (ALCL)
  - Classical HL post-auto-HSCT consolidation
  - Relapsed primary cutaneous ALCL and CD30-expressing mycosis fungoides
- Received Breakthrough Therapy Designation from FDA in frontline advanced classical Hodgkin lymphoma based on positive phase 3 ECHELON-1 trial data; submitted sBLA November 2017
- Since 2011 U.S. approval, more than 20,000 Hodgkin lymphoma patients around the world treated
- Antibody-drug conjugate that targets CD30, which is expressed in classical Hodgkin lymphoma as well as other types of lymphoma
- Only drug FDA-approved specifically for systemic anaplastic large cell lymphoma
- Seattle Genetics has full commercialization rights in the U.S. and Canada.

Seattle Genetics is an emerging global multi-product biotechnology company that develops and commercializes innovative antibody-based therapies for the treatment of cancer. We are focused on a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. In addition to one marketed product, we are advancing a strong product pipeline designed to address significant unmet medical needs.

ADCETRIS: Broad Global Development Plan

Our lead program, ADCETRIS® (brentuximab vedotin) is the first in a new class of ADCs, and, in collaboration with Takeda Pharmaceutical Company Limited, is commercially available in more than 65 countries. We believe that ADCETRIS has the potential to be the foundation of care for CD30-expressing lymphomas. We are executing a broad global development plan for potential indications in earlier lines of therapy and other CD30-expressing lymphomas. Across both corporate and investigator trials, ADCETRIS is being evaluated as single-agent or combination treatment in more than 70 clinical trials.

In June 2017, we reported positive results from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS in combination with chemotherapy in newly diagnosed advanced Hodgkin lymphoma, for which the FDA granted Breakthrough Therapy Designation in September 2017. We submitted a supplemental Biologics License Application to the FDA in early November requesting approval of ADCETRIS in this disease setting.

ADCs: Integral Part of Cancer Therapy

ADCs are continuing to advance as an important therapeutic modality, both as single agents and as part of various combination regiments for both hematologic malignancies and solid tumors. ADCETRIS is one of more than 20 proprietary and collaborator ADC programs in clinical development using our technology.

We are also advancing two late-stage ADCs, enfortumab vedotin for urothelial cancer under our collaboration with Astellas and tisotumab vedotin for cervical cancer under our collaboration with Genmab, each in potentially registrational clinical trials. We have multiple clinical trials ongoing and planned with ladiratuzumab vedotin (SGN-LIV1A) for breast cancer, as well as several other internal clinical and preclinical programs. Our strong product pipeline provides opportunities across hematologic malignancies and solid tumors.

Our goal is to employ the power of our ADC technology to improve efficacy and decrease toxicity in a target-specific manner across multiple tumor types. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.

ADVANCING INDUSTRY-LEADING ADC Technology



Potential to Improve Patient Outcomes with Targeted Therapies

Our antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary industry-leading technology, we are able to optimize each ADC to potentially improve outcomes for patients.

In our ADCs, stable linkers attach a potent synthetic cell-killing (cytotoxic) agent to an antibody. The antibody is targeted against a specific tumor-associated receptor on cancer cell surfaces. Our linker systems relase the cytotoxic agent once inside the targeted cells. This target-specific approach is intended to enhance antitumor activity and minimize toxic effects across mutliple tumor types.

By targeting specific tumor-associated receptors on the surface of cancer cells, ADCs have the potential to spare non-targeted cells and reduce toxic side effects.

As shown in the illustration above, other approaches to cancer treatment target pathways inside the cell or activate immune cells. Various combinations of these novel modalities are likely to be the future of treatment in oncology.

In addition to advancing our ADC research, we are applying our expertise in targets and antibodies to the area of immuno-oncology. We believe that through targeted killing of tumor cells and immunogenic cell death, ADCs could become the preferred partner for immuno-oncology agents, and are testing brentuximab vedotin, enfortumab vedotin and ladiratuzumab vedotin (SGN-LIV1A) in combinations with checkpoint inhibitors. We also have a collaboration and license agreement with Unum Therapeutics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies. Additionally, we are conducting clinical trials with SEA-CD40, a novel immuno-oncology agent using our sugar-engineered antibody technology, and SGN-2FF, an oral small molecule.

Extending Our Opportunities through ADC Technology Collaborations

Beyond broad internal development of our antibody-drug conjugate technology, we have entered into collaborations with a number of industry-leading biotechnology and pharmaceutical companies. These licensing activities extend the reach of our technology as collaborators investigate numerous targets in many therapeutic areas. Across both internal and collaborator programs, there are more than 20 ADCs in clinical development using our technology.

In addition to extending the reach of our technology into additional programs, our ADC technology licensing agreements have generated more than $350 million to date. They also provide us with future pipeline opportunities through co-development or opt-in rights to new ADC product candidates.

Find more details on our ADC technology collaborator program at our website, SeattleGenetics.com.

abbvie · astellas · Celldex therapeutics · Genentech · Genmab · Pfizer · Progenics

Strong Oncology Pipeline

Brentuximab Vedotin

HODGKIN LYMPHOMA (HL)	ECHELON-1: Frontline classical HL	Phase 3: sBLA submitted
	CHECKMATE 812: Relapsed HL (+ nivolumab)	Phase 3
	Frontline HL in patients 60+ (+ nivolumab)	Phase 2
	Second-line HL (+ nivolumab)	Phase 2
NON-HODGKIN LYMPHOMA (NHL)	ECHELON-2: Frontline CD30-expressing mature T-cell lymphoma (MTCL) (also known as PTCL)	Phase 3: Enrollment complete
	Relapsed NHL (+ nivolumab)	Phase 1/2

Other Programs

SOLID TUMORS		
Enfortumab vedotin*	EV-201: Urothelial cancer	Phase 2: Potentially registrational
	EV-103: Urothelial cancer (+ checkpoint inhibitor)	Phase 1
Tisotumab vedotin**	Cervical cancer	Phase 2: Potentially registrational
Ladiratuzumab vedotin (SGN-LIV1A)	Triple negative breast cancer (TNBC) (+ checkpoint inhibitor)	Phase 2
	I-SPY 2: HER2-negative breast cancer	Phase 2
	Breast cancer	Phase 1
LYMPHOMA		
Denintuzumab mafodotin	Diffuse large B-cell lympyhoma	Phase 2
SGN-CD19B	Non-Hodgkin lymphoma	Phase 1
LEUKEMIA		
SGN-CD123A	Acute myeloid leukemia	Phase 1
MYELOMA		
SGN-CD352A	Multiple myeloma	Phase 1
SGN-CD48A	Multiple myeloma	Phase 1
IMMUNO-ONCOLOGY		
SEA-CD40	Advanced cancer (+/- checkpoint inhibitor)	Phase 1
SGN-2FF	Advanced solid tumors	Phase 1
ACTR-BCMA	Multiple myeloma	Phase 1

* Program being developed in collaboration with Astellas
** Program being developed in collaboration with Genmab

These are investigational uses/agents and efficacy/safety have not been established.
Visit seattlegenetics.com for the most current pipeline status.

SeattleGenetics®

SEATTLE GENETICS, INC.
21823 30TH DRIVE SOUTHEAST
BOTHELL, WASHINGTON 98021
www.SeattleGenetics.com

Senior Management

Clay B. Siegall, Ph.D.
PRESIDENT & CHIEF EXECUTIVE OFFICER

Eric L. Dobmeier
CHIEF OPERATING OFFICER

Jonathan Drachman, M.D.
CHIEF MEDICAL OFFICER AND EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT

Vaughn B. Himes, Ph.D.
CHIEF TECHNICAL OFFICER

Todd E. Simpson
CHIEF FINANCIAL OFFICER

Darren Cline
EXECUTIVE VICE PRESIDENT, COMMERCIAL

Jean I. Liu, J.D.
GENERAL COUNSEL, EXECUTIVE VICE PRESIDENT, LEGAL AFFAIRS

Christopher Pawlowicz
EXECUTIVE VICE PRESIDENT, HUMAN RESOURCES

Elaine Waller, Pharm.D.
EXECUTIVE VICE PRESIDENT, REGULATORY AFFAIRS

Board of Directors

Clay B. Siegall, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD OF DIRECTORS, SEATTLE GENETICS, INC.

Srinivas Akkaraju, M.D., Ph.D.
FOUNDER AND MANAGING GENERAL PARTNER AT SAMSARA BIOCAPITAL

Felix J. Baker, Ph.D.
CO-MANAGING MEMBER OF BAKER BROS. ADVISORS

David W. Gryska
EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, INCYTE CORPORATION

Marc E. Lippman, M.D.
KATHLEEN AND STANLEY GLASER PROFESSOR AND DEPUTY DIRECTOR, SYLVESTER COMPREHENSIVE CANCER CENTER, UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE

John A. Orwin
CHIEF EXECUTIVE OFFICER, RELYPSA, INC.

Nancy A. Simonian, M.D.
CHIEF EXECUTIVE OFFICER, SYROS PHARMACEUTICALS, INC.

Daniel G. Welch
EXECUTIVE PARTNER, SOFINNOVA VENTURES

Recent Highlights

- November 2017: Announced fourth US approval of ADCETRIS® (brentuximab vedotin) for primary cutaneous ALCL and CD30-expressing mycosis fungoides, the most common subtypes of cutaneous T-cell lymphoma
- November 2017: Initiated phase 1b trial of enfortumab vedotin in combination with immune checkpoint inhibitor therapies for first- or second-line treatment of patients locally advanced or metastatic urothelial cancer
- November 2017: Submitted supplemental Biologics License Application to FDA for ADCETRIS in frontline advanced Hodgkin lymphoma; application based on positive results from the phase 3 ECHELON-1 clinical trial; FDA recently granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy for frontline advanced classical Hodgkin lymphoma
- November 2017: Announced presentation of data from broad ADCETRIS development program at December's American Society of Hematology 2017 Annual Meeting, including positive phase 3 ECHELON-1 clinical trial results in Plenary Scientific Session
- October 2017: Announced additional clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer
- October 2017: Initiated pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer
- October 2017: Announced plans to initiate a phase 2 study of tisotumab vedotin in patients with advanced cervical cancer; study provides opportunity for accelerated approval
- August 2017: Announced purchase of biologics manufacturing facility from Bristol-Myers Squibb

SGEN Quick Facts

NASDAQ SYMBOL
SGEN

CASH AND INVESTMENTS
$470 million as of September 30, 2017

COMMON STOCK OUTSTANDING
Approximately 140 million shares

FISCAL YEAR END
December 31

YEAR FOUNDED
1998

EMPLOYEES
>1,000

GLOBAL HEADQUARTERS
Bothell, WA USA

EUROPEAN OFFICES
Zug, Switzerland

INVESTORS
Peggy Pinkston, 425.527.4160
Investors@seagen.com

MEDIA
Brandi Robinson, 425.527.2910
Media@seagen.com

TECHNOLOGY LICENSING
BusinessDevelopment@seagen.com

GENERAL INQUIRIES
Contact@seagen.com

FOLLOW US ON TWITTER
@SeattleGenetics

 Certain of the statements made in this fact sheet and elsewhere are forward looking. These statements are based on factors that involve risks and uncertainties, and actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks and uncertainties associated with fulfilling sales, marketing and distribution requirements; the acceptance of ADCETRIS in the marketplace; the status of reimbursement from third-party payors; risks inherent in clinical stage development and risks that our collaborators do not fulfill their obligations. For additional information on these and other factors that could affect Seattle Genetics' results, see the reports filed by the company with the SEC, which are available at www.sec.gov. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.